Provided by Tiger Trade Technology Pte. Ltd.

AbCellera Biologics

13.91
-0.6800-4.66%
Post-market: 13.930.0200+0.14%19:57 EDT
Volume:7.79M
Turnover:109.84M
Market Cap:4.51B
PE:-25.50
High:14.65
Open:14.59
Low:13.79
Close:14.59
52wk High:15.02
52wk Low:2.75
Shares:324.00M
Float Shares:221.00M
Volume Ratio:1.29
T/O Rate:3.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5455
EPS(LYR):-0.4902
ROE:-17.30%
ROA:-10.39%
PB:5.03
PE(LYR):-28.38

Loading ...

Jazz Pharmaceuticals, AbCellera collaborate for TCE multispecific antibodies

TIPRANKS
·
Jun 17

Jazz Pharmaceuticals, AbCellera team up on T-cell engaging multispecific antibodies for GI cancers

Reuters
·
Jun 17

Jazz Pharmaceuticals and Abcellera Announce Collaboration to Discover Next-Generation T-Cell Engaging Multispecific Antibodies

THOMSON REUTERS
·
Jun 17

Abcellera Biologics - Collaboration Includes $56 Mln Upfront and up to $792 Mln Option Fees per Program

THOMSON REUTERS
·
Jun 17

Abcellera Biologics - Jazz Has Exclusive Option to Develop and Commercialize Antibodies From Collaboration

THOMSON REUTERS
·
Jun 17

Is AbCellera (ABCL) Using Boardroom Oncology Talent to Redefine Its Clinical Ambitions?

Simply Wall St.
·
Jun 13

AbCellera shareholders elect John Montalbano, Stephen Quake as Class III directors

Reuters
·
Jun 13

AbCellera files Form 3 for director Victor Sandor, reporting no beneficial ownership

Reuters
·
Jun 12

AbCellera Biologics Adds Victor Sandor to Board

TIPRANKS
·
Jun 06

AbCellera appoints Victor Sandor to board as independent director

Reuters
·
Jun 05

Abcellera Appoints DR. Victor Sandor to Its Board of Directors

THOMSON REUTERS
·
Jun 05

Is AbCellera (ABCL) Turning Upgraded Earnings Forecasts Into a Durable Clinical-Stage Business Model?

Simply Wall St.
·
Jun 04

A Look At AbCellera Biologics (ABCL) Valuation After Improved Earnings Outlook And Sector Outperformance

Simply Wall St.
·
Jun 02

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), AbCellera Biologics (ABCL) and Indivior (INDV)

TIPRANKS
·
May 22

AbCellera publishes corporate overview on internal antibody pipeline, platform expansion strategy

Reuters
·
May 20

AbCellera director John S. Montalbano acquires 20,000 common shares for $95,400

Reuters
·
May 19

AbCellera Biologics (ABCL) Q4 Revenue Surge Tests High 20.1x P/S Growth Narrative

Simply Wall St.
·
May 13

AbCellera Biologics Bets Big on 2026 Trial Catalysts

TIPRANKS
·
May 13

Stock Track | AbCellera Biologics Plummets 11.65% Intraday Amid Concerns Over Continued Losses and Rising R&D Expenses Despite Q1 Beat

Stock Track
·
May 12

Analysts’ Opinions Are Mixed on These Healthcare Stocks: West Pharmaceutical Services (WST), CVRx (CVRX) and AbCellera Biologics (ABCL)

TIPRANKS
·
May 12